Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19
Status:
Completed
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a world
health issue during the last months, affecting mostly countries with a high metabolic risk,
like Mexico. Patients with type 2 diabetes (T2D) have an increased risk of any kind of
infection as well as an increased mortality risk. Hyperglycemia has been established as an
important predictor of mortality in patients with T2D and SARS-CoV-2. The standard treatment
of hyperglycemia in hospitalized patients has been basen on insulin schemes, but recently
evidence suggest the utility of some other drugs, reducing the risk of hypoglucemia and
increasing the probability of a proper metabolic control. The goal of this study is to
compare the utility of dipeptidyl peptidase-4 inhibitor (DPP4i) as a combination with insulin
on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 and
hyperglycemia.